In FY2025, FDA completed 3,732 inspections of registered drug and device establishments, including 355 for-cause inspections, showing why regulatory readiness must extend beyond premarket authorization. In 2026, medical device regulatory submissions require teams to choose the right 510(k), De Novo, or PMA pathway and support it with clear clinical, performance, risk, and quality evidence.
Moreover, organizations managing broader medical-product portfolios must align device-specific requirements with relevant pharma regulations and post-authorization controls. This guide explains how to build stronger submissions, use eSTAR correctly, reduce review deficiencies, and keep evidence ready for FDA scrutiny.
Table of Contents
What Are Medical Device Regulatory Submissions?
Medical device regulatory submissions provide FDA with the regulatory, technical, performance, and quality evidence needed to evaluate whether a device can legally enter the U.S. market. Depending on the device classification and risk, manufacturers may use a 510(k), De Novo, or PMA pathway. In addition, each submission should clearly explain the device design, intended use, testing strategy, risk controls, and supporting data. Therefore, a well-structured premarket submission helps reduce review questions and supports a more efficient FDA evaluation.
Why Submission Quality Matters for FDA Review and Compliance?
Strong medical device regulatory submissions help FDA reviewers understand the device, its risks, and the evidence supporting safety and performance. However, incomplete testing, poor pathway selection, weak predicate comparisons, or inconsistent quality-system records can trigger additional questions and delay review. Moreover, gaps between submission claims and controlled design or manufacturing records may create problems during later inspections. Therefore, submission quality supports both efficient FDA review and long-term regulatory compliance.
How the Main FDA Premarket Routes Differ
FDA premarket pathways differ by device risk, novelty, available predicate evidence, and the level of data needed to support market authorization. Therefore, regulatory teams must choose the correct route early and align testing, documentation, and submission strategy with that pathway.
The four main routes and submission structures to understand are:
- 510(k) and Substantial Equivalence (PDF)
- De Novo for Novel Device Types (PDF)
- PMA for High-Risk Devices (PDF)
- eSTAR and Electronic Submission Structure (PDF)
The infographic below summarizes the main FDA medical device submission routes and shows how 510(k), De Novo, PMA, and eSTAR fit into premarket regulatory strategy.
510(k) and Substantial Equivalence (PDF)
A 510(k) compares a new device with a legally marketed predicate to establish substantial equivalence. FDA reviews intended use, technological characteristics, and supporting performance evidence.
De Novo for Novel Device Types (PDF)
De Novo provides a pathway for novel devices that lack a suitable predicate. It applies when general or special controls can adequately manage the device’s identified risks.
Download De Novo Classification Process (Evaluation of Automatic Class III Designation) Here
PMA for High-Risk Devices (PDF)
PMA applies mainly to high-risk Class III medical devices. Manufacturers must provide robust scientific, clinical, and technical evidence to support device safety and effectiveness.
Download Introduction to the Premarket Approval Application (PMA) Program Here
eSTAR and Electronic Submission Structure (PDF)
eSTAR provides a standardized electronic structure for FDA medical device submissions. It helps teams organize required information consistently and reduce submission completeness issues.
Download Electronic Submission Template for Medical Device 510(k) Submissions Here
How to Choose the Right FDA Premarket Pathway
Choose the FDA pathway before building the submission because each route requires different evidence. A 510(k) uses a predicate, De Novo supports novel low- to moderate-risk devices, and PMA applies to high-risk Class III devices. Therefore, early selection helps teams plan testing, clinical data, and regulatory documentation efficiently.
The table below compares 510(k), De Novo, and PMA across the key factors that regulatory teams should evaluate before preparing a submission.
| FDA Pathway | Predicate Availability | Typical Device Risk | Regulatory Standard | Evidence Burden | FDA Outcome |
|---|---|---|---|---|---|
|
510(k) |
Suitable legally marketed predicate required |
Usually Class II; some Class I |
Demonstrate substantial equivalence to the predicate |
Comparative — device comparison plus relevant performance, safety, and other supporting data |
510(k) Clearance / Substantially Equivalent determination |
|
De Novo |
No suitable legally marketed predicate |
Novel low- to moderate-risk device; Class I or II after classification |
Show that general controls, or general and special controls, can provide reasonable assurance of safety and effectiveness |
Moderate to substantial — risk analysis, performance evidence, proposed controls, and clinical evidence when needed |
De Novo Granted; FDA establishes a new Class I or II device type |
|
PMA |
Predicate comparison does not determine eligibility |
High-risk Class III device |
Provide reasonable assurance of safety and effectiveness |
Highest — extensive scientific evidence and often clinical data, plus manufacturing and other required information |
PMA Approval |
FDA describes 510(k) as a comparative substantial-equivalence pathway, while De Novo creates a new classification for eligible novel devices and PMA uses an independent safety-and-effectiveness standard for Class III devices.
The infographic below compares 510(k), De Novo, and PMA from early pathway selection through the evidence FDA reviews before market authorization.
How to Reduce FDA Submission Deficiencies Before Filing
Regulatory teams can reduce deficiencies by reviewing medical device regulatory submissions in a fixed sequence before filing. First, confirm device classification, predicate strategy, and pathway selection; then verify testing, clinical evidence, labeling, and risk documentation. In addition, check every eSTAR section for completeness and align submission claims with controlled QMS records. Therefore, a disciplined pre-submission review helps prevent inconsistencies, reduce FDA questions, and support a smoother review process.
Final Words
In FY2025, FDA analyzed 65 PMA-related inspections, and the median time from an inspection request to the start of the inspection reached 87 days. This data shows why regulatory teams should connect medical device regulatory submissions with inspection-ready quality systems from the beginning. Therefore, teams that align technical evidence, manufacturing controls, and QMS records early can reduce compliance risks and support a more predictable FDA review process.
Medical Devices & IVDs EU Registration
We guide companies through medical device and IVD EU registration by supporting MDR and IVDR requirements, technical documentation, and structured processes for compliant market access.
FAQ
Choose the pathway based on device classification, risk, predicate availability, and required evidence. Regulated life-sciences teams should confirm this strategy before starting major testing or submission work.
Yes. Differences between submission claims, testing records, design controls, risk files, or manufacturing documentation can trigger FDA questions and create problems during later inspections.
Maintain controlled design records, risk files, testing evidence, labeling, change controls, and key QMS documentation. These records should stay consistent with the approved device and support future FDA inspections.
References
Alireza Zarei is the founder and CEO of Zamann Pharma Support GmbH in Germany. He pairs 20 years in GMP—beginning in a lab in 2005—with front-line global project delivery for companies such as Boehringer Ingelheim, Roche, BioNTech, Takeda, Fresenius Medical Care, Biotest, ratiopharm and others. He focuses on innovative validation and qualification procedures, master data management strategies, end-to-end LIMS implementation and care, with pragmatic advice on general Quality Management topics and management level OpEx consulting. Together with his team he also created Pharmuni.com as the leading GMP learning platform in the industry.